Novartis to buy immunotherapy start-up

Novartis (NVS) has agreed to acquire CoStim Pharmaceuticals, which focuses on using the immune system to battle cancer.

Terms of the deal weren't disclosed.

Immunotherapy is one of the hottest areas of cancer research, with Merck, AstraZeneca and Bristol-Myers among those working in the field. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs